BioMarin Pharmaceuticals (BMRN) Stock: Buy, Sell, or Hold?
BMRN - BioMarin Pharmaceuticals Inc
$55.95
-0.68 (-1.20%)
▼
5d:
+2.32%
30d:
-8.8%
90d:
-7.17%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Oct 26, 2026
1d
Get Alerted When BMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BMRN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: BMRN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$117.53
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$72.97
23.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMRN is currently trading at $55.95, which is considered slightly low relative to its 30-day fair value range of $54.99 to $62.61. The stock's valuation (Forward PE: 8.7) is in line with its historical norms (9.4). Remarkably, the market is currently pricing in an annual earnings decline of 2.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BMRN is in a uptrend. The price is approaching resistance at $57.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BMRN scores 79/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $91.56 (+63.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BMRN is in a uptrend. The price is approaching resistance at $57.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BMRN scores 79/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $91.56 (+63.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$54.99 -
$62.61
Company Quality Score
73/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (79/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 63.6% below Wall St target ($91.56)
- BULLISH: Bottoming setup score 79/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$54.99 -
$62.61
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$53.93
Resistance Level
$57.59
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.71
Wall Street Target
$91.56
(+63.6%)
Revenue Growth (YoY)
19.9%
Earnings Growth (YoY)
-81.3%
Profit Margin
2.1%
Valuation Discount vs History
-2.6% cheaper
PE vs Historical
8.7 vs 9.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.6%
(market-implied from PE analysis)
1-Year Target
$54.50
(-3%)
2-Year Target
$53.08
(-5%)
3-Year Target
$51.70
(-8%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
$55.77
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 83.1%)
$430.34
(+669%)
Base:
(SPY PE: 8.7, Growth: 83.1%)
$188.83
(+238%)
Bear:
(PE: 7.4, Growth: 83.1%)
$160.51
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (9x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Forward PE: 9.40 | Forward EPS (Implied): $5.95
Bull Case
$67.56
(+21%)
Analyst growth 15.0%, PE expands to 9.9
Base Case
$55.95
(0%)
Market implied 0.0%, PE stable at 9.4
Bear Case
$42.80
(-24%)
Severe decline -15.0%, PE contracts to 8.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.7 to 9.4
Stabilization Target:
$60.35
(+7.9%)
PE Expansion Potential:
+7.9%
Share & Embed Analysis
Last updated: October 24, 2026 3:08 AM ET
Data refreshes hourly during market hours. Next update: 4:08 AM
Data refreshes hourly during market hours. Next update: 4:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 50 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 48 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 43 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$37 | 59 HOLD |
Advanced BMRN Option Strategies
Professional options setups generated by AI based on today's BMRN price and gamma walls.
